SFM
SYRE icon

Soros Fund Management’s Spyre Therapeutics SYRE Stock Holding History

Soros Fund Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125,000
Closed -$2.02M – 257
2025
Q1 		$2.02M Sell
125,000
-125,000
-50% -$2.6M 0.03% 188
2024
Q4 		$5.82M Buy
250,000
+105,000
+72% +$3.08M 0.09% 149
2024
Q3 		$4.26M Hold
145,000
– – 0.06% 137
2024
Q2 		$3.41M Buy
145,000
+114,962
+383% +$3.88M 0.06% 151
2024
Q1 		$1.14M Buy
+30,038
New +$870K 0.02% 181
2018
Q3 		– Sell
-8,256
Closed -$2.18M – 233
2018
Q2 		$2.18M Buy
+8,256
New +$2.03M 0.04% 193

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Soros Fund Management's SYRE Position: Q2 2025 in Review

Soros Fund Management sold out of Spyre Therapeutics (SYRE) in Q2 2025, closing a stake of 125,000 shares — an estimated $2.02M sold.

Soros Fund Management first reported a position in SYRE in Q2 2018 and held it in 6 quarters. The position peaked at $5.82M in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • Soros Fund Management reported no remaining Spyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Soros Fund Management sold 125,000 Spyre Therapeutics shares in Q2 2025, an estimated $2.02M.
  • Soros Fund Management first reported a position in Spyre Therapeutics in Q2 2018 and held it in 6 quarters.
  • Soros Fund Management's Spyre Therapeutics position peaked at $5.82M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on Soros Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.